Study links a gut metabolite from histidine to Alzheimer's-related decline
On 26 June 2026, Nature Communications published a study led by University of Wisconsin-Madison researchers reporting that higher blood levels of imidazole propionate (ImP), made by gut bacteria metabolising the amino acid histidine, were associated with lower preclinical cognitive scores and steeper decline in 1,196 cognitively unimpaired adults, along with higher levels of Alzheimer's-related markers. A common genetic variant, rs7969761, was linked to higher ImP and to Alzheimer's risk, and a Mendelian randomisation analysis estimated a 1.16-fold higher risk per standard deviation of genetically predicted ImP. In mice, chronic ImP increased amyloid plaques and tau phosphorylation and impaired the blood-brain barrier, and cell work traced the barrier effect to endothelial cells while GSK3-beta inhibition blocked tau hyperphosphorylation in primary neurons. The authors describe ImP as a potential target and call for more work; the findings are associations plus animal and cell models, and no study has yet shown that lowering ImP in people reduces dementia risk.
The record ends here. Everything below this line is invented.
What if a consumer ImP score was bought by a long-term-care insurer?
Part one
The Histidine Number
The kit arrived on a Tuesday, in a box the size of a paperback, and Solveig took it to work.
It was called the ImP Index: swab your tongue, mail the tube, and in nine days an app tells you where your gut bacteria put you. Biome Ledger had sold four million. Harbor Mutual had bought the index; Solveig's job was to price it.
Her number came during the actuarial review: ninety-one, top decile, which put a third of the extra long-term-care premium on her.
She read the footnote, being an actuary: an estimate, not a diagnosis, from one draw. It did not say the compound — imidazole propionate, made by gut bacteria from histidine, an amino acid in every protein she ate — had been measured once.
Two floors up, the pricing committee had voted: a tier launching the following year, discount for the bottom half, surcharge for her. Her sister Karin had called about selling the house to pay for their mother's care. Solveig said what she always said — "let me look at the numbers" — because their mother had begun leaving the kettle on and calling her by her childhood nickname.
The trial came that week: a phase two study of a pill that stopped the bacteria making the compound. Solveig qualified on her number, read the consent form twice and signed.
Fourteen months later, at the interim readout, the pill did what it promised: ImP went to zero.
The treated arm declined faster.
What’s real
- Higher ImP tracked with faster decline in 1,196 adults.
- A common variant linked ImP levels to Alzheimer's risk.
- In mice the compound worsened amyloid and tau pathology.
- The work is association, mice and cells, not a treatment.
What’s invented
- Biome Ledger, the ImP Index, and Harbor Mutual.
- The enzyme-blocker trial and its interim findings.
- Solveig, her sister Karin, and the withdrawn tier.
- The second kit and its reading of 42.
Part two: The Second Kit
Part two isn’t on sale yet. Check back soon.
Filed under medicine, microbiome, alzheimers, biomarkers.